Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

The Supreme Court’s 2024 Loper Bright decision marked a historic turning point for federal regulation, especially for businesses navigating the complex interplay between the FDA, FTC, and DEA in the cannabinoid sector. For decades, the Chevron doctrine meant federal courts often deferred to agencies’ interpretations of ambiguous statutory language. Now, with Chevron gone, courts independently determine what the law means—even when the relevant agency disagrees.
This seismic shift presents both risk and opportunity for anyone working in regulated cannabinoid markets. The loss of automatic deference does not mean a regulatory "free for all"—far from it. However, it does upend familiar compliance strategies and places a new premium on statutory language, Congressional intent, and the evidentiary underpinnings of agency rules.
In this analysis, we explore how recent court decisions are reshaping the compliance landscape for cannabinoid markets in 2025–2026. We’ll examine:
For forty years, the Chevron doctrine gave federal agencies like the FDA, Federal Trade Commission (FTC), and Drug Enforcement Administration (DEA) considerable leeway. If Congress’s statutory language was ambiguous, courts almost always deferred to the agency’s reasonable interpretation. This gave regulators substantial power to adapt enforcement or guidance without waiting for Congressional updates—especially useful in fast-moving science and technology sectors.
The June 2024 Loper Bright decision upended this framework. Now, courts must perform their own, independent reading of ambiguous statutes, regardless of agencies’ opinions. This means courts can strike down agency rules or guidance wherever they overstep the clear statutory text or cannot justify actions within Congressional mandates.
For the cannabinoid industry—where federal law (like the 2018 Farm Bill and FDCA) is often fragmentary, and many critical distinctions (e.g., lawful hemp vs. illegal analogs, what constitutes an adulterated food or supplement, etc.) are subject to agency interpretation—this judicial shift dramatically increases both uncertainty and opportunity.
Key takeaway: No more automatic deference for FDA/FTC/DEA rulemaking: Only statutory language and clear Congressional intent prevail in legal disputes.
The FDA has long held that CBD is not a permissible dietary ingredient or additive for foods and supplements mainly because it was first investigated as a drug (Epidiolex). The agency has issued warnings, seized products, and published guidance documents—largely relying on its interpretation of the Food, Drug, and Cosmetic Act (FDCA).
Under the Loper Bright standard, courts now scrutinize:
Any regulatory enforcement (like warning letters for CBD-infused foods or supplements) can be directly challenged if the statutory basis is vague or unsupported. This is especially true for novel or minor cannabinoids where Congressional intent is unclear.
Takeaway for compliance: Always document your product’s compliance with applicable statutes (not just agency guidance!), maintain deep records of scientific substantiation, and be prepared for rapidly shifting regulatory interpretations.
The FTC maintains broad authority over deceptive advertising, including claims about cannabinoid content, health benefits, and safety. It typically relies on its interpretive rules and long-standing guides about what constitutes misleading or substantiated claims.
Takeaway for compliance: Update ad review and claims substantiation processes. When faced with regulatory inquiries, center your defense and compliance efforts around the explicit language of the statutes, not just the FTC’s guides or FAQ pages.
In the wake of Loper Bright, the DEA finds itself under new judicial scrutiny, especially regarding how it schedules substances or defines "analogs."
Takeaway for compliance: When launching, manufacturing, or distributing new cannabinoid products in 2025, conduct your own legal analysis. Have a well-reasoned statutory and scientific rationale for why your products are permissible under the CSA and Farm Bill.
Federal courts are rapidly becoming the battlefield for unresolved questions in cannabinoid regulation. Key litigation and enforcement patterns include:
The fallout from the Loper Bright decision is transforming how compliance teams, marketers, and product strategists approach FDA, FTC, and DEA regulation of cannabinoids.
Instead of relying exclusively on agency interpretations, industry actors must:
While the regulatory waters are more turbulent, companies willing to invest in legal research and adaptive compliance strategies will be best positioned to thrive in this new era.
For ongoing analysis, compliance tools, and real-time case tracking, visit CannabisRegulations.ai and leverage our professional resources to keep your business ahead of legal change.